Declaración de PrivacidadTérminos de UsoEntrar Registro
 
HomeCompanyBiotechnologyPortfolioBusiness ModelInvestment ManagementPress RoomContact
BIOCROSS
  • Scientific source: Dr. E. Méndez, Dr J.M. Carazo, CNB-UAM 
  • Line of work: Biomarker based on the monoclonal antibody EMS 
  • Development stage: Validation stage
  • Value proposition: High sensitivity and specificity in assessment during the early stages of the disease
  • Demographic data: 
    • 24.3 million people in the world live with Alzheimer's (8 million in the USA).
    • Expected to grow to 80 million sufferers by the year 2040
    • 4.6 million new cases every year
    • 60% in developing countries, rising to 71% in 2040
    • 7th cause of death in the USA
    • The direct and indirect costs of Alzheimer's to the American health service are estimated at $148 billion
BIOCROSS

Early Alzheimer's diagnosis test.

Development of a new biomarker with high sensitivity and specificity for the early assessment of Alzheimer's disease  using a molecular test of β-amiloide peptides in biological fluids.